← Product Code [NRI](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/NRI) · K061842

# QUANTA LITE PBC SCREEN IGG/IGA ELISA (K061842)

_Inova Diagnostics, Inc. · NRI · Oct 18, 2006 · Immunology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/NRI/K061842

## Device Facts

- **Applicant:** Inova Diagnostics, Inc.
- **Product Code:** [NRI](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/NRI.md)
- **Decision Date:** Oct 18, 2006
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 866.5090
- **Device Class:** Class 2
- **Review Panel:** Immunology

## Indications for Use

The QUANTA Lite™ PBC Screen IgG/IgA ELISA is an enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative detection of anti-mitochondrial antibodies, gp210 antibodies, and sp100 antibodies of the IgG and/or IgA class in human serum. The presence of mitochondrial, gp210, and sp100 antibodies can be used in conjunction with clinical findings as an aid in the diagnosis of primary biliary cirrhosis.

## Device Story

QUANTA Lite™ PBC Screen IgG/IgA ELISA is an in vitro diagnostic assay for human serum samples. It utilizes enzyme-linked immunosorbent assay (ELISA) technology to detect specific autoantibodies (anti-mitochondrial, gp210, and sp100) associated with primary biliary cirrhosis. Performed in clinical laboratories by trained technicians; results are interpreted by physicians in conjunction with clinical findings to support diagnosis. The assay provides semi-quantitative data, assisting clinicians in identifying autoimmune markers indicative of liver disease.

## Clinical Evidence

No clinical data provided in the document; substantial equivalence is based on bench testing and performance characteristics typical of ELISA-based immunological assays.

## Technological Characteristics

Semi-quantitative ELISA; polystyrene microplate with breakaway 12x8 microwells; antigens: recombinant MIT3, synthetic gp210, synthetic sp100; enzyme-conjugate: HRP-labeled goat anti-human IgG/IgA; substrate: TMB chromogen; stop solution: 0.344M sulfuric acid; detection: spectrophotometric OD at 450/620 nm; manual/automated plate reader required.

## Regulatory Identification

An antimitochondrial antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the antimitochondrial antibodies in human serum. The measurements aid in the diagnosis of diseases that produce a spectrum of autoantibodies (antibodies produced against the body's own tissue), such as primary biliary cirrhosis (degeneration of liver tissue) and chronic active hepatitis (inflammation of the liver).

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number:
k061842

B. Purpose for Submission:
New Device

C. Measurand:
Anti-Mitochondrial (MIT3) Antibodies
Anti-gp210 Antibodies
Anti-sp100 Antibodies

D. Type of Test:
Semi-quantitative ELISA

E. Applicant:
INOVA Diagnostics, Inc.

F. Proprietary and Established Names:
QUANTA LITE™ PBC Screen IgG/ IgA ELISA

G. Regulatory Information:
1. Regulation section:
21 CFR §866.5090 Antimitochondrial antibody immunological test system
2. Classification:
Class II
3. Product code:
DBM, Antimitochondrial Antibody
NRI, Autoantibodies, Nuclear Pore Glycoprotein (gp210)
NUM Autoantibodies, nuclear body protein, sp100
4. Panel:
Immunology 82

H. Intended Use:
1. Intended use(s):
The QUANTA LITE™ PBC Screen IgG/IgA ELISA is an enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative detection of mitochondrial antibodies, gp210, and sp100 antibodies of the IgG and/or IgA class in human serum. The presence of mitochondrial, gp210, and sp100 antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of primary biliary cirrhosis.
2. Indication(s) for use:
Same as intended use.
3. Special conditions for use statement(s):
For prescription use only.
4. Special instrument requirements:
Microplate reader capable of measuring OD at 450 nm (or 620 for dual wavelength readings).

I. Device Description:
Each device contains the following: polystyrene microplate strips with breakaway (12x8) microwells coated with PBC Screen antigen (mixture of purified MIT3, sp100

{1}

and gp210 antigens); high positive, low positive, and negative controls (human serum); horseradish peroxidase (HRP) wash concentrate; HRP sample diluent; HRP Anti-human IgG/IgA conjugate (goat); TMB chromogen; and 0.344M sulfuric acid stop solution.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

QUANTA LITE™ M2 EP (MIT3)

QUANTA LITE™ gp210 ELISA

QUANTA LITE™ sp100 ELISA

2. Predicate 510(k) number(s):

k052262 (MIT3)

k040885 (gp210)

k050662 (sp100)

3. Comparison with predicate:

|  Similarities  |   |   |
| --- | --- | --- |
|  Item | New Device | Predicate Devices  |
|   | QUANTA LITE™ PBC Screen IgG/IgA | Individual devices: QUANTA LITE™ M2 EP (MIT3); QUANTA LITE™ gp210; and QUANTA LITE™ sp100  |
|  Intended use | To aid in the diagnosis of Primary Biliary Cirrhosis (PBC). | Same  |
|  Technology | ELISA | Same  |
|  Assay Format | Semi-quantitative | Same  |
|  Platform | 96 well microtiter plates | Same  |
|  Controls | 3 levels: negative, low positive and high positive Pre-diluted human serum. Ready to use. | Same  |
|  Sample type and dilution | Serum at 1:101 | Same  |
|  Sample volume required | 5 μL | Same  |
|  Wash Concentrate | 40X Tris-buffered saline and Tween 20 | Same  |
|  HRP Sample Diluent | Tris-buffered saline, Tween 20, protein stabilizer, preservative | Same  |
|  Substrate | TMB Chromogen | Same  |
|  Stop solution | 0.344M Sulphuric acid | Same  |
|  Incubation times | 30-30-30 minutes | Same  |
|  OD reading | 450 nm (or 620 for dual wavelength readings) | Same  |
|  Cut-off | 25.0 Units | Same  |

{2}

|  Differences  |   |   |
| --- | --- | --- |
|  Item | Device | Predicate  |
|  Antigen | Mixture of three antigens in one assay: purified recombinant M2 EP MIT3, highly purified synthetic gp210 peptide, and highly purified synthetic sp100 peptide | Individual antigens in three separate assays: purified recombinant M2 EP MIT3; highly purified synthetic gp210 peptide; and highly purified synthetic sp100 peptide  |
|  Enzyme-Conjugate | Horseradish Peroxidase, Goat Anti-human IgG/IgA | Horseradish Peroxidase, Goat Anti-human IgG  |

# K. Standard/Guidance Document Referenced (if applicable):

CLSI (NCCLS) H18-A3, Vol. 24(38), 2004: Processing Blood Specimens
CLSI (NCCLS) C24-A2, Vol. 19(5), 2006: Statistical quality control

# L. Test Principle:

A mixture containing affinity-purified recombinant antigen MIT3 which includes immunodominant portions of PDC-E2, BCOADC-E2, and OGDC-E2, a purified fragment of the sp100 protein, and a purified fragment of the gp100 protein is bound to the wells of a polystyrene microwell plate under conditions that will preserve the antigen in their native state. Pre-diluted controls and diluted patient sera are added to separate wells, allowing any mitochondrial antibodies present to bind to the immobilized antigen. Unbound sample antibodies are washed away and an enzyme labeled anti-human IgG/IgA conjugate is added to each well. A second incubation allows the enzyme labeled anti-human IgG/IgA to bind to any patient antibodies, which have become attached to the microwells. After washing away any unbound enzyme labeled anti-human IgG/IgA, the remaining enzyme activity is measured by adding a chromogenic substrate and measuring the intensity of the color that develops. The assay can be evaluated spectrophotometrically by measuring and comparing the color intensity that develops in the patient wells with the color in the control wells.

# M. Performance Characteristics (if/when applicable):

# 1. Analytical performance:

# a. Precision/Reproducibility:

The intra-assay precision was determined using seven serum samples, with PBC Screen concentration levels ranged from 13.6 to 61.6 Units/mL. These seven samples were tested five times. The positive samples had  $\leq 3.7\%$  CV, and the negative samples had  $\leq 2.4\%$  CV as listed below.

|  Specimen | A | B | C | D | E | F | G  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  Mean units | 61.6 | 39.8 | 27.9 | 13.6 | 27.5 | 26.5 | 23.6  |
|  SD | 2.3 | 1.0 | 0.8 | 0.3 | 0.9 | 0.6 | 0.5  |
|  CV (%) | 3.7 | 2.4 | 3.0 | 2.4 | 3.2 | 2.2 | 2.2  |

{3}

The inter-assay precision was determined using eight serum samples in duplicate, assayed twice daily (once in the morning and once in the afternoon) for three days. The positive samples had ≤ 6.1% CV, and the negative samples had ≤ 9.2% CV as listed below.

|  Specimen | A | B | C | D | E | F | G | H  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  Mean units | 67.5 | 8.4 | 29.7 | 35.2 | 6.3 | 31.5 | 29.8 | 25.2  |
|  SD | 1.7 | 0.3 | 1.2 | 0.6 | 0.6 | 1.9 | 1.3 | 0.25  |
|  CV % | 2.6 | 3.6 | 4.0 | 1.6 | 9.2 | 6.1 | 4.5 | 1.0  |

b. Linearity/assay reportable range:

No claims were made regarding linearity for the assay. It is a semi-quantitative assay with results reported out as negative (0.0 – 20.0 Units), positive (≥ 25 Units), or equivocal (20.1 – 24.9 Units), when results are interpreted by comparison to the low positive control value of 25 Units. Specimens with positive results may be tested for the presence of individual MIT3, gp210, and sp100 antibodies with MIT3, gp100, and sp100 specific ELISA assays.

c. Traceability, Stability, Expected values (controls, calibrators, or methods): There is no recognized standard or reference material for antibodies to the PBC Screen multi-antigen mixture. The positive and negative controls are prepared in house and arbitrary units are assigned during the development process.

d. Detection limit:

Not applicable.

e. Analytical specificity:

Interference by endogenous substances: No data provided. The package insert states that grossly hemolyzed, lipemic, microbially contaminated, heat-treated, or specimens containing visible particulate should be avoided in this assay.

Crossreactivity study to other autoantibodies was performed. Results were under in section for 'Clinical specificity'.

f. Assay cut-off:

The cut-off value of 25 units/mL for the PBC Screen IgG/ IgA assay was established from a combined panel of 1012 specimens collected from 520 asymptomatic healthy individuals and 492 patients with a variety of non-PBC diseases, i.e. 29 autoimmune and infectious diseases: 3 anti-Saccharomyces cerevisiae (ASCA), 4 antinuclear antibody (ANA), 3 tissue transglutaminase antibody (tTg), 2 gastric parietal antibody (GPA), 2 glomerular basement membrane antibody (GBM), 7 Helicobacter pylori, and 8 cytomegalovirus (CMV); 213 autoimmune hepatitis (AIH); 48 Primary Sclerosing Cholangitis (PSC); 10 AIH/PSC; 8 autoimmune cholangitis (AIC); 9 cryptogenic hepatitis; 1 drug-induced hepatitis; 11 vanishing bile duct syndrome (VBDS); 71 HBV; 78 HCV; 3 autoimmune hepatitis type 2; 11 alcoholic liver disease. Using the 25 units/mL cut-off, 98.1% (510/520) of the normal samples were

{4}

negative. Of the non-PBC samples, 89% (438/492) were negative. If the possible undiagnosed overlap syndromes (AIH/PCS, VBDS, AIC, cryptogenic hepatitis, AIH, and AMA-negative PBC) were excluded from the non-PBC group, 92% (229/249) of the samples were negative.

## 2. Comparison studies:

a. Method comparison with predicate:

A total of 1209 specimens from seven clinical sites, were tested on PBC Screen IgG/IgA ELISA assay and the individual MIT3, gp210 and sp100 ELISA assays. The samples consisted of 440 PBC (426 definite PBC and 14 AIH/PBC overlap); 48 PSC; 149 viral hepatitis (HBV or HCV); 23 non-PBC liver diseases; 29 infectious or other autoimmune diseases, and 520 healthy individuals. Equivocals were excluded from the percent agreement calculations. Results are summarized below.

|   | Individual QUANTA LITE™ MIT3, gp210, or sp100 ELISA assay  |   |   |   |   |
| --- | --- | --- | --- | --- | --- |
|   |   |  Positive | Equivocal* | Negative | Total  |
|  QUANTA Lite™ PBC Screen IgG/IgA | Positive | 437 | 6 | 8 | 445  |
|   |  Equivocal* | 10 | 5 | 8 | 23  |
|   |  Negative | 2 | 3 | 730 | 732  |
|   |  Total | 439 | 14 | 738 | 1177  |

*Equivocal results were excluded from the analysis

Positive percent agreement = 99.5% (437/439)

Negative Percent Agreement = 98.9% (730/738)

Overall Agreement = 99.2% (1167/1177)

The 14 Equivocal samples with the individual assays had the following diagnosis: 2 normal, 2 AMA+ PBC, 2 PSC, 2 PBC, 3 HBV, 2 HCV, 1 Alc. Liver Dis. The 23 Equivocal samples with the PBS Screen assay had the following diagnosis: 20 non-PBC samples and 3 PBC samples.

b. Matrix comparison:

All assay use serum as matrix.

## 3. Clinical studies:

a. Clinical Sensitivity and Specificity:

The same samples in the method comparison study were used for the determination of clinical sensitivity and specificity. Equivocal results were included as negative. The sensitivity was 95.9% (422/440) and the specificity was 96.1% (739/769).

|  N=1209 |  | Quanta Lite™ PBC Screen IgG/ IgA  |   |   |
| --- | --- | --- | --- | --- |
|  Patient Group | n | Positive | Equivocal* | Negative  |
|  PBC | 440 | 422 | 3 | 15  |
|  Non-PBC (769): healthy controls (520); other disease controls (249) | 769 | 30 | 20 | 719  |
|  Total | 1209 | 452 | 23 | 734  |

*Equivocal results were included as negative.

{5}

Sensitivity: 95.9% (422/440); (95% CI: 93.6% to 97.6%)

Specificity: 96.1% (739/769) (95% CI: 94.5% to 97.4%)

The 20 Equivocal samples with the PBC Screen assay had the following diagnosis: 12 AIH, 2 Alc. Liver Dis, 1 HBV, 2 HCV, 2 PSC, 1 Non-liver disease.

b. Other clinical supportive data (when a. is not applicable):

Not applicable.

4. Clinical cut-off:

Same as assay cut-off.

5. Expected values/Reference range:

Expected values in the normal population should be negative.

A panel of 520 asymptomatic, healthy individuals residing in the USA was tested with the PBC Screen IgG/IgA assay and with the three individual MIT3, gp210, sp100 ELISA assays. Age and gender data were available for 307 specimens and unavailable for the remaining specimens. The samples were from 150 male and 157 female subjects with age ranging from 18-78 years. The average PBC Screen value for this population was 6.6 units with a median value of 4.6 units. The PBC Screen IgG/IgA assay had a specificity of 98.1% (510/520). The 10 positive samples with PBC Screen assay had the following results: one sample had 105 units and showed a classic AMA staining on HEp-2 cells by IFA whereas the other 9 positive had values ranging from 28-46 units. On further testing, one of these 10 specimen did not have sufficient serum, 6 were positive and 1 equivocal with the MIT3 IgG assay, one sample was negative with all three individual assays, and one was negative with the gp210 and sp100 assays but positive with the MIT3 assay only. Since these were donor samples, it is not possible to verify the true clinical status of the reactive specimens.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

---

**Source:** [https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/NRI/K061842](https://fda.innolitics.com/submissions/IM/subpart-f%E2%80%94immunological-test-systems/NRI/K061842)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com